NASDAQ:ICLR - Icon Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$137.21 +0.36 (+0.26 %)
(As of 07/18/2018 08:45 AM ET)
Previous Close$136.85
Today's Range$135.7750 - $137.70
52-Week Range$97.12 - $140.26
Volume381,860 shs
Average Volume199,865 shs
Market Capitalization$7.40 billion
P/E Ratio25.46
Dividend YieldN/A
Beta0.45
Icon logoICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Debt-to-Equity Ratio0.29
Current Ratio1.85
Quick Ratio1.85

Price-To-Earnings

Trailing P/E Ratio25.46
Forward P/E Ratio22.68
P/E Growth2.14

Sales & Book Value

Annual Sales$1.76 billion
Price / Sales4.22
Cash Flow$6.6157 per share
Price / Cash20.74
Book Value$22.02 per share
Price / Book6.23

Profitability

EPS (Most Recent Fiscal Year)$5.39
Net Income$281.48 million
Net Margins14.80%
Return on Equity26.56%
Return on Assets14.53%

Miscellaneous

Employees13,250
Outstanding Shares54,080,000
Market Cap$7,400.98

The Truth About Cryptocurrencies

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) announced its earnings results on Thursday, May, 3rd. The medical research company reported $1.42 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.41 by $0.01. The medical research company earned $620.13 million during the quarter, compared to the consensus estimate of $562.61 million. Icon had a net margin of 14.80% and a return on equity of 26.56%. Icon's revenue was up 43.6% compared to the same quarter last year. During the same period last year, the firm earned $1.29 earnings per share. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $5.91-6.11 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.99. The company issued revenue guidance of $2.52-2.64 billion, compared to the consensus revenue estimate of $2.25 billion.

What price target have analysts set for ICLR?

9 equities research analysts have issued 1 year price targets for Icon's stock. Their predictions range from $114.00 to $152.00. On average, they anticipate Icon's share price to reach $132.2222 in the next year. This suggests that the stock has a possible downside of 3.6%. View Analyst Ratings for Icon.

What is the consensus analysts' recommendation for Icon?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Icon's key competitors?

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Mr. Ciaran Murray, Former Exec. Chairman (Age 55)
  • Dr. Steven A. Cutler, CEO & Director (Age 58)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 39)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer

Has Icon been receiving favorable news coverage?

News coverage about ICLR stock has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Icon earned a news impact score of 0.20 on Accern's scale. They also gave news headlines about the medical research company an impact score of 46.01 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Icon's major shareholders?

Icon's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include American Capital Management Inc. (1.54%), Peregrine Capital Management LLC (0.53%), Mckinley Capital Management LLC Delaware (0.50%), Bank of Montreal Can (0.33%), Summit Creek Advisors LLC (0.24%) and LVM Capital Management Ltd. MI (0.10%). View Institutional Ownership Trends for Icon.

Which institutional investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Peregrine Capital Management LLC, Summit Creek Advisors LLC, Reliance Trust Co. of Delaware, Fulton Bank N.A. and Welch & Forbes LLC. View Insider Buying and Selling for Icon.

Which institutional investors are buying Icon stock?

ICLR stock was acquired by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Bank of Montreal Can, Fox Run Management L.L.C., Campbell & CO Investment Adviser LLC, American Capital Management Inc., LVM Capital Management Ltd. MI, Atria Investments LLC and Fisher Asset Management LLC. View Insider Buying and Selling for Icon.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $137.21.

How big of a company is Icon?

Icon has a market capitalization of $7.40 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.